Sclerosis MDPI

07/12/2025

📖 New Paper: "Fingolimod and Neuroinflammation in MS: Representing CD8+ T-Cell Dynamics Through Mathematical Modeling and Clinical Evidence"

🌟 This study developed a computational model to quantify fingolimod’s effects on immune dynamics in multiple sclerosis, with a focus on blocking CD8⁺ T-cell migration. The model accurately reproduced the timing and extent of T-cell sequestration observed in clinical data. These results highlight the potential of computational modeling to clarify fingolimod’s mechanism of action and support more personalized treatment strategies.

🔗 Read the full article: https://brnw.ch/21wY8Uk

Background: Multiple sclerosis (MS), a debilitating chronic disease of the central nervous system, is characterized by both inflammatory and neurodegenerative processes that lead to demyelination and neuronal damage. While MS remains incurable, therapies like fingolimod can slow disease progression....

07/12/2025

📖 New Review: "Recent Advances in Localized Scleroderma"

🌟 This Review highlights major advances in the pathogenesis and management of localized scleroderma, including evidence for somatic mosaicism and single-cell RNA sequencing insights revealing IFN-γ–driven pro-fibrotic crosstalk among immune and fibroblast populations. It also underscores the importance of the JAK–STAT pathway, supported by the discovery of a STAT4 gain-of-function monogenic form. Management is becoming more standardized, with methotrexate as first-line systemic therapy and emerging targeted options—such as abatacept, tocilizumab, and JAK inhibitors—for refractory disease.

🔗 Read the full article: https://brnw.ch/21wY8Uj

06/12/2025

📖 New Research: "Exploring the Links Between Ankylosing Spondylitis and Amyotrophic Lateral Sclerosis: A Bidirectional Mendelian Randomization Study"

🌟 This bidirectional Mendelian randomization study examined whether genetic susceptibility to ankylosing spondylitis or amyotrophic lateral sclerosis causally influences the risk of the other condition. Using GWAS-derived instruments and multiple sensitivity analyses, the study found no evidence of a causal relationship in either direction. These results suggest that previously noted co-occurrences are unlikely to reflect shared genetic causality.

🔗 Read the full article: https://brnw.ch/21wY7Qv

06/12/2025

📖 New Paper: "Cognitive Impairment Screening in Multiple Sclerosis Using CoGeval: Clinical and Functional Predictors in a Mexican Cohort"

🌟 In this cross-sectional study of 81 adults with multiple sclerosis in Mexico, nearly half screened positive for cognitive impairment using CogEval. Impairment was strongly associated with higher disability levels and poorer manual dexterity, while age and gait speed were not independent predictors. The findings support CogEval as a practical screening tool to identify patients who may benefit from further neuropsychological evaluation and rehabilitation.

🔗 Read the full article: https://brnw.ch/21wY7Qw

06/12/2025

📖 New Paper: "Workplace Adjustment Measures to Maintain the Ability to Work of People with Multiple Sclerosis"

🌟 This qualitative study explored workplace challenges faced by people with multiple sclerosis and gathered their suggestions for improving workability. Participants reported limited access to health-related support and insufficient workplace adjustments, highlighting the need for flexible hours, fatigue-management strategies, and better coordination among employers, healthcare providers, and labor services. The findings emphasize that education about MS and tailored technical and organizational accommodations are essential for helping affected individuals remain employed.

🔗 Read the full article: https://brnw.ch/21wY7PZ

Background: Multiple sclerosis (MS) leads to early retirement in one-third of patients. The aim of this study is to analyze the difficulties at work and to collect suggestions for support measures at the workplace to maintain the ability to work for people with MS. Methods: Qualitative interviews we...

05/12/2025

📖 New Research: "Possible Reasons for the Suboptimal Response of the Cladribine Course in Daily Practice: An Independent Analysis of Data from 12 Russian Clinics and the Results of Post-Registration Studies in Other Countries"

🌟 This study evaluated the long-term effects of daily cladribine tablets on multiple sclerosis in 235 patients from 12 neurological centers across Russia, with an average follow-up of 3.4 years. Cladribine reduced relapse frequency overall, although patients who switched from natalizumab or ocrelizumab showed a notably higher risk of exacerbations. The findings suggest that crossover from second-line therapies—particularly natalizumab—may be suboptimal, whereas earlier switching from first-line treatments appears more favorable.

🔗 Read the full article: https://brnw.ch/21wY5Xe

Objectives: The purpose of this study was to analyze the effect of daily intake of cladribine tablets on the course of multiple sclerosis (MS) while monitoring for 1–4 years during and after the course in several neurological clinics from different regions of the Russian Federation. Materials and ...

05/12/2025

📖 New Research: "Evaluation of Early Initiation of Disease-Modifying Treatment for Patients with Multiple Sclerosis Within a Real-World Population for Long-Term Outcomes"

🌟 This real-world study from the Scottish Multiple Sclerosis Register compared long-term outcomes in Relapsing Remitting Multiple Sclerosis (RRMS) patients who started Disease-Modifying Treatment (DMT) early versus those treated late or never. After 11–13 years of follow-up, there were no significant differences in disability progression or clinicoradiological outcomes, although patient satisfaction was higher with early treatment. The lack of observable benefit may reflect limitations such as small matched groups, reliance on older injectable therapies, and group assignment based on diagnosis rather than first symptoms.

🔗 Read the full article: https://brnw.ch/21wY5Xm

04/12/2025

📖 New Review: "Antithrombotic and Anti-Inflammatory Health Promoting Pharmacological Properties of Chalcones and Their Derivatives Against Atherosclerosis and CVD"

🌟 Chalcones, a class of flavonoid compounds, are recognized for their unique biological properties, and especially for their antithrombotic, anti-inflammatory, and antioxidant health-promoting properties against inflammation-related disorders. Chalcones are phytochemicals naturally found in plants, fruits, and vegetables, such as tomatoes, apples, and licorice. Their characteristic chemical structure, which includes two aromatic rings and an α,β-unsaturated carbonyl group, makes them particularly versatile for pharmaceutical use. At the same time, chalcones exhibit strong antioxidant activity by neutralizing free radicals and enhancing endogenous antioxidant defense systems, such as glutathione. Structural modifications have improved their biological activity, leading to important applications in the treatment of atherosclerosis and cardiovascular diseases, cancer, neurodegenerative diseases, and inflammatory disorders. In addition, they have been successfully used in agriculture as natural pesticides and in the food industry as antioxidant additives. This review demonstrates the interdisciplinary importance of chalcones, highlighting the need for further research into their molecular mechanisms of action. A deeper understanding of their properties may open new avenues for the development of innovative drugs and environmentally friendly applications. In this way, chalcones can be a decisive factor in improving human health and environmental sustainability.

🔗 Read the full article: https://brnw.ch/21wY3O0

04/12/2025

📖 A collection of 11 papers, this Special Issue "Recent Advances in Understanding ", edited Prof. Dr. Joerg Henes is now available in form.

➡ Special Issue link: https://brnw.ch/21wY3Nh
➡ Access the free reprint: https://brnw.ch/21wY3Ng

14/11/2025

📖 New Review: "Multiple Sclerosis & Pharmacotherapeutic Treatment: A Pedagogic Tutorial for Healthcare Providers"

🌟 This review provides an up-to-date overview of multiple sclerosis pathophysiology, current treatments, and emerging therapies, aiming to enhance the knowledge base of healthcare professionals and researchers, facilitating informed decision-making and contributing to ongoing research efforts.

🔗 Read the full article: https://brnw.ch/21wXu4B

12/11/2025

📖 New Research: "The Use of 18F-FDG-PET in Systemic Sclerosis with Myocardial Involvement: The Scleroderma Heart Study"

🌟 Authors evaluated ¹⁸F-FDG PET/CT for detecting cardiac involvement in scleroderma. Among 16 patients, half showed positive myocardial uptake, mostly physiological rather than disease-related. Follow-up revealed no link between PET results, treatment response, or survival. The study suggests that cardiac PET has limited clinical value in scleroderma cardiomyopathy and requires further validation in larger cohorts.

🔗 Read the full article: https://brnw.ch/21wXpIH

04/11/2025

📖 New Review: "Genetic Variants and Heat Shock Proteins: Unraveling Their Interplay in Neurodegenerative Sclerosis—A Comprehensive Review"

🌟 This review analyzed studies on single nucleotide variants (SNVs) in HSP genes (Hsp40, Hsp70, Hsp90, DNAJC7) and their potential contribution to amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) pathophysiology. Despite existing findings, the authors highlight a clear need for more targeted genetic studies to clarify how HSP variants influence disease onset and progression.

🔗 Read the full article: https://brnw.ch/21wXbp7